glp 1 medications oral GLP-1 Orforglipron Is Approved for Obesity Oral GLP‑1 Therapy Type 2

Reviewed by Emily Bigby, MD, Physician with Ivm Health Disclaimer: The information presented reflects clinical observations and emerging research

This indication can be covered under Medicare Part D and potentially certain Florida Blue commercial plans with prior authorization distinct from the excluded weight-loss benefit

Key benefits include: Decreased appetite and caloric intake

Weeks 4 to 8: If the approach is going to work, most patients begin seeing meaningful changes in this window

Discontinuation before pregnancy : There is not enough human data yet to support GLP-1 medications during pregnancy and lactation, so currently it is not recommended